HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Hangzhou Bioer Technology - Key Judgement on Performance Sustainability and Other Concerns

Pre-IPO Broncus Holding Corporation - The Strength and the Concerns

Pre-IPO MicroPort MedBot - The Core Products, the Business Model and the Concerns

Pre-IPO Clarity Medical Group - The Prospects Are Still Not Brighter

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Hangzhou Bioer Technology / Equity Capital Markets

<p>On June 11, <a href="https://www.smartkarma.com/entities/hangzhou-bioer-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:33513:1" rel="noopener">Hangzhou Bioer Technology (BIOER HK)</a> officially started the IPO process by submitting a prospectus to the HKEX. Bioer was founded in 2002 and has developed for 19 years, but its performance soared during the COVID-19 and ushered in great changes. Therefore, this may be the best time to launch an IPO for Bioer. However, aside from the outstanding financial performance brought by the pandemic, there are also some concerns and potential risks that worth the attention of investors.</p>

On June 11, Hangzhou Bioer Technology (BIOER HK) officially started the IPO process by submitting a prospectus to the HKEX. Bioer was founded in 2002 and has developed for 19 years, but its performance soared during the COVID-19 and ushered in great changes. Therefore, this may be the best time to launch an IPO for Bioer. However, aside from the outstanding financial performance brought by the pandemic, there are also some concerns and potential risks that worth the attention of investors.

Pre-IPO Hangzhou Bioer Technology - Concerns Behind the Outstanding Performance